JP2015535277A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015535277A5 JP2015535277A5 JP2015540256A JP2015540256A JP2015535277A5 JP 2015535277 A5 JP2015535277 A5 JP 2015535277A5 JP 2015540256 A JP2015540256 A JP 2015540256A JP 2015540256 A JP2015540256 A JP 2015540256A JP 2015535277 A5 JP2015535277 A5 JP 2015535277A5
- Authority
- JP
- Japan
- Prior art keywords
- halo
- alkyl
- alkoxy
- independently selected
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims description 21
- 239000001257 hydrogen Substances 0.000 claims description 21
- 150000001875 compounds Chemical class 0.000 claims description 19
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 19
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 16
- -1 hydroxy, hydroxy Chemical group 0.000 claims description 15
- 125000003545 alkoxy group Chemical group 0.000 claims description 14
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 150000002431 hydrogen Chemical class 0.000 claims description 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 5
- 150000002829 nitrogen Chemical group 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 4
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims description 4
- 125000004414 alkyl thio group Chemical group 0.000 claims description 4
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims description 3
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 21
- 150000003839 salts Chemical class 0.000 claims 21
- 239000011780 sodium chloride Substances 0.000 claims 21
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 2
- 125000005549 heteroarylene group Chemical group 0.000 claims 2
- 230000002062 proliferating Effects 0.000 claims 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- 206010003816 Autoimmune disease Diseases 0.000 claims 1
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims 1
- 206010012818 Diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 1
- 125000000732 arylene group Chemical group 0.000 claims 1
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims 1
- 230000001684 chronic Effects 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000005113 hydroxyalkoxy group Chemical group 0.000 claims 1
- 200000000018 inflammatory disease Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 description 19
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261721920P | 2012-11-02 | 2012-11-02 | |
US61/721,920 | 2012-11-02 | ||
US201361772028P | 2013-03-04 | 2013-03-04 | |
US61/772,028 | 2013-03-04 | ||
PCT/IB2013/059846 WO2014068527A1 (en) | 2012-11-02 | 2013-11-01 | Bruton's tyrosine kinase inhibitors |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015535277A JP2015535277A (ja) | 2015-12-10 |
JP2015535277A5 true JP2015535277A5 (US07585860-20090908-C00112.png) | 2016-09-08 |
JP6178861B2 JP6178861B2 (ja) | 2017-08-09 |
Family
ID=49596360
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015540256A Expired - Fee Related JP6178861B2 (ja) | 2012-11-02 | 2013-11-01 | ブルトン型チロシンキナーゼ阻害剤 |
Country Status (27)
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ703607A (en) | 2012-08-10 | 2018-02-23 | Boehringer Ingelheim Int | Heteroaromatic compounds as bruton’s tyrosine kinase (btk) inhibitors |
WO2014039899A1 (en) | 2012-09-10 | 2014-03-13 | Principia Biopharma Inc. | Pyrazolopyrimidine compounds as kinase inhibitors |
CN103848810A (zh) | 2012-11-30 | 2014-06-11 | 北京赛林泰医药技术有限公司 | 鲁顿酪氨酸激酶抑制剂 |
US8895750B2 (en) | 2013-03-14 | 2014-11-25 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as BTK inhibitors |
BR112015021856A2 (pt) * | 2013-03-15 | 2017-07-18 | Janssen Pharmaceutica Nv | processos e intermediários para a preparação de um medicamento |
JP6495886B2 (ja) | 2013-03-15 | 2019-04-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Btk阻害剤としての複素環式芳香族化合物 |
US9156847B2 (en) * | 2013-03-15 | 2015-10-13 | Janssen Pharmaceutica Nv | Processes and intermediates for preparing a medicament |
HUE051336T2 (hu) * | 2013-08-19 | 2021-03-01 | Taris Biomedical Llc | Többadagos gyógyszeradagoló eszköz |
RU2677884C2 (ru) | 2013-09-30 | 2019-01-22 | Гуанчжоу Иннокэа Фарма Тек Ко., Лтд. | Замещенные никотинимидные ингибиторы втк, их получение и применение в терапии раковых, воспалительных и аутоиммунных заболеваний |
WO2015116485A1 (en) | 2014-01-29 | 2015-08-06 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as btk inhibitors |
EP3107544B1 (en) | 2014-02-21 | 2020-10-07 | Principia Biopharma Inc. | Salts and solid form of a btk inhibitor |
WO2015185998A2 (en) * | 2014-04-11 | 2015-12-10 | Acerta Pharma B.V. | Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase |
CN105085474B (zh) * | 2014-05-07 | 2018-05-18 | 北京赛林泰医药技术有限公司 | 鲁顿酪氨酸激酶抑制剂 |
GB201410430D0 (en) | 2014-06-11 | 2014-07-23 | Redx Pharma Ltd | Compounds |
CN106687446B (zh) * | 2014-07-18 | 2020-04-28 | 百济神州(北京)生物科技有限公司 | 作为t790m/wt-egfr的选择性和不可逆的激酶抑制剂的5-氨基-4-氨甲酰基-吡唑化合物及其用途 |
WO2016019237A2 (en) * | 2014-07-31 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
CN105884747B (zh) * | 2014-08-28 | 2021-01-05 | 首药控股(北京)有限公司 | 一种制备布鲁顿酪氨酸激酶(btk)激酶抑制剂的制备方法 |
EA036269B1 (ru) | 2014-12-18 | 2020-10-21 | Принсипиа Биофарма Инк. | Лечение пузырчатки |
WO2016192074A1 (en) * | 2015-06-04 | 2016-12-08 | Merck Sharp & Dohme Corp. | Btk inhibitors |
US20180305350A1 (en) | 2015-06-24 | 2018-10-25 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
EA201890730A1 (ru) | 2015-09-16 | 2018-10-31 | Локсо Онколоджи, Инк. | Производные пиразолопиримидина в качестве ингибиторов btk для лечения злокачественного новообразования |
PT3377484T (pt) * | 2015-11-17 | 2023-12-14 | Merck Patent Gmbh | Métodos para tratamento de esclerose múltipla utilizando compostos de pirimidina e piridina com atividade inibidora de btk |
DK3390390T3 (da) | 2015-12-16 | 2021-12-06 | Boehringer Ingelheim Int | Bipyrazolylderivater egnede til behandling af autoimmunsygdomme |
EA035132B1 (ru) * | 2015-12-16 | 2020-04-30 | Локсо Онколоджи, Инк. | Соединения, которые можно применять в качестве ингибиторов киназы |
WO2017123695A1 (en) | 2016-01-13 | 2017-07-20 | Boehringer Ingelheim International Gmbh | Isoquinolones as btk inhibitors |
CN107021963A (zh) | 2016-01-29 | 2017-08-08 | 北京诺诚健华医药科技有限公司 | 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用 |
EP3433246B1 (en) | 2016-03-24 | 2022-05-04 | Mission Therapeutics Limited | 1-cyano-pyrrolidine derivatives as dbu inhibitors |
KR102404759B1 (ko) * | 2016-05-16 | 2022-05-31 | 쑤저우 시노벤트 파마슈티칼즈 씨오., 엘티디. | Btk 억제제로서의 5-아미노피라졸 카르복사미드 유도체 및 그것의 제조 방법 및 제약학적 조성물 |
IL293621B2 (en) | 2016-06-29 | 2023-09-01 | Principia Biopharma Inc | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(oxane-3-yl)piperazine-1-yl)penta-2-ananitrile |
GB201616511D0 (en) * | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
TWI771327B (zh) * | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
CN110545826A (zh) | 2016-12-03 | 2019-12-06 | 朱诺治疗学股份有限公司 | 用于与激酶抑制剂组合使用治疗性t细胞的方法和组合物 |
KR20200067850A (ko) | 2017-10-06 | 2020-06-12 | 포르마 세라퓨틱스 인크. | 유비퀴틴 특이적 펩티다제 30의 억제 |
WO2019091440A1 (zh) * | 2017-11-10 | 2019-05-16 | 苏州信诺维医药科技有限公司 | 作为btk抑制剂的5-氨基吡唑甲酰胺化合物的晶型i |
CN111225912B (zh) * | 2017-11-10 | 2020-11-10 | 苏州信诺维医药科技有限公司 | 作为btk抑制剂的5-氨基吡唑甲酰胺化合物及其制备方法 |
WO2019091438A1 (zh) * | 2017-11-10 | 2019-05-16 | 苏州信诺维医药科技有限公司 | 作为btk抑制剂的5-氨基吡唑甲酰胺化合物的无定型固体分散体 |
CN108530436B (zh) * | 2018-05-17 | 2020-12-29 | 黄传满 | 一种吡唑类化合物及其制备方法和应用 |
RS64321B1 (sr) | 2018-10-05 | 2023-08-31 | Forma Therapeutics Inc | Fuzionisani pirolini koji se ponašaju kao inhibitori ubikvitin specifične proteaze 30 (usp30) |
BR112021018168B1 (pt) | 2019-03-21 | 2023-11-28 | Onxeo | Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer |
CN113906011A (zh) * | 2019-05-21 | 2022-01-07 | 詹森药业有限公司 | 用于制备btk抑制剂的方法和中间体 |
AU2020378630A1 (en) | 2019-11-08 | 2022-05-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
TW202317099A (zh) * | 2020-09-10 | 2023-05-01 | 美商絡速藥業公司 | 用於製備(s)-5-胺基-3-(4-((5-氟-2-甲氧基苯甲醯胺基)甲基)苯基)-1-(1,1,1-三氟丙烷-2-基)-1h-吡唑-4-甲醯胺之方法及中間體 |
US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
CN115611810A (zh) * | 2021-07-16 | 2023-01-17 | 深圳市塔吉瑞生物医药有限公司 | 取代的吡唑类化合物及包含该化合物的组合物及其用途 |
TW202342444A (zh) * | 2022-02-04 | 2023-11-01 | 美商理通製藥公司 | 特定化學實體、組合物及方法 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
US6326469B1 (en) | 1994-04-22 | 2001-12-04 | Sugen, Inc. | Megakaryocytic protein tyrosine kinases |
GB9608435D0 (en) * | 1996-04-24 | 1996-06-26 | Celltech Therapeutics Ltd | Chemical compounds |
EP1436265A4 (en) * | 2001-09-27 | 2004-12-15 | Smithkline Beecham Corp | CHEMICALS |
ES2376765T3 (es) | 2006-04-11 | 2012-03-16 | Vertex Pharmaceuticals, Inc. | Tiazoles, imidazoles y pirazoles útiles como inhibidores de proteína quinasas |
SI2526933T1 (sl) | 2006-09-22 | 2015-07-31 | Pharmacyclics, Inc. | Inhibitorji Bruton tirozin kinaze |
FR2908409B1 (fr) | 2006-11-10 | 2009-01-09 | Sanofi Aventis Sa | Pyrazoles substituees,compositions les contenant,procede de fabrication et utilisation |
JP2010533715A (ja) * | 2007-07-17 | 2010-10-28 | アムジエン・インコーポレーテツド | 複素環系pkb調節剤 |
MX2011000661A (es) * | 2008-07-16 | 2011-05-25 | Pharmacyclics Inc | Inhibidores de tirosina cinasa de bruton para el tratamiento de tumores solidos. |
PL2324008T3 (pl) | 2008-07-24 | 2012-09-28 | Nerviano Medical Sciences Srl | 3,4-diarylopirazole jako inhibitory kinazy białkowej |
WO2011029046A1 (en) * | 2009-09-04 | 2011-03-10 | Biogen Idec Ma Inc. | Bruton's tyrosine kinase inhibitors |
EP2582668B1 (en) * | 2010-06-16 | 2016-01-13 | Bristol-Myers Squibb Company | Carboline carboxamide compounds useful as kinase inhibitors |
NZ703607A (en) * | 2012-08-10 | 2018-02-23 | Boehringer Ingelheim Int | Heteroaromatic compounds as bruton’s tyrosine kinase (btk) inhibitors |
CN103848810A (zh) * | 2012-11-30 | 2014-06-11 | 北京赛林泰医药技术有限公司 | 鲁顿酪氨酸激酶抑制剂 |
FR3002733B1 (fr) | 2013-03-04 | 2015-08-14 | Servier Lab | Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
WO2015157408A2 (en) | 2014-04-09 | 2015-10-15 | Donaldson Company, Inc. | Self-supporting folded sheet material, filter elements, and methods |
CN105085474B (zh) * | 2014-05-07 | 2018-05-18 | 北京赛林泰医药技术有限公司 | 鲁顿酪氨酸激酶抑制剂 |
-
2013
- 2013-11-01 JP JP2015540256A patent/JP6178861B2/ja not_active Expired - Fee Related
- 2013-11-01 MX MX2015005422A patent/MX2015005422A/es unknown
- 2013-11-01 ES ES13792494.0T patent/ES2625944T3/es active Active
- 2013-11-01 EA EA201500393A patent/EA201500393A1/ru unknown
- 2013-11-01 KR KR1020157014092A patent/KR101668574B1/ko active IP Right Grant
- 2013-11-01 MD MDA20150035A patent/MD20150035A2/ro not_active Application Discontinuation
- 2013-11-01 BR BR112015009624A patent/BR112015009624A2/pt active Search and Examination
- 2013-11-01 SG SG11201502893WA patent/SG11201502893WA/en unknown
- 2013-11-01 US US14/439,478 patent/US20150291554A1/en not_active Abandoned
- 2013-11-01 AU AU2013340345A patent/AU2013340345B2/en not_active Ceased
- 2013-11-01 PE PE2015000569A patent/PE20151070A1/es not_active Application Discontinuation
- 2013-11-01 AP AP2015008381A patent/AP2015008381A0/xx unknown
- 2013-11-01 GE GEAP201313816A patent/GEP201606597B/en unknown
- 2013-11-01 WO PCT/IB2013/059846 patent/WO2014068527A1/en active Application Filing
- 2013-11-01 CN CN201380065731.8A patent/CN105008344B/zh not_active Expired - Fee Related
- 2013-11-01 CA CA2888960A patent/CA2888960C/en not_active Expired - Fee Related
- 2013-11-01 EP EP13792494.0A patent/EP2914586B1/en active Active
- 2013-11-04 TW TW102139984A patent/TWI518080B/zh not_active IP Right Cessation
-
2015
- 2015-04-27 PH PH12015500940A patent/PH12015500940A1/en unknown
- 2015-04-29 CO CO15098489A patent/CO7350624A2/es unknown
- 2015-04-30 CR CR20150228A patent/CR20150228A/es unknown
- 2015-04-30 NI NI201500059A patent/NI201500059A/es unknown
- 2015-04-30 IL IL238571A patent/IL238571A0/en unknown
- 2015-04-30 TN TNP2015000168A patent/TN2015000168A1/fr unknown
- 2015-05-01 DO DO2015000100A patent/DOP2015000100A/es unknown
- 2015-05-04 CL CL2015001168A patent/CL2015001168A1/es unknown
- 2015-12-09 HK HK15112141.6A patent/HK1211293A1/xx unknown
-
2017
- 2017-06-16 US US15/624,969 patent/US10266513B2/en active Active
-
2019
- 2019-03-08 US US16/296,319 patent/US10815213B2/en active Active
-
2020
- 2020-09-18 US US17/025,026 patent/US20210002251A1/en not_active Abandoned